Martingale Asset Management L P Sells 27,920 Shares of Abbott Laboratories $ABT

Martingale Asset Management L P lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 11.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,116 shares of the healthcare product maker’s stock after selling 27,920 shares during the period. Martingale Asset Management L P’s holdings in Abbott Laboratories were worth $28,143,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after acquiring an additional 162 shares in the last quarter. United Bank boosted its holdings in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Abbott Laboratories by 4.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 262,889 shares of the healthcare product maker’s stock valued at $35,756,000 after purchasing an additional 11,036 shares during the period. Finally, Hudock Inc. raised its holdings in Abbott Laboratories by 2.7% in the 2nd quarter. Hudock Inc. now owns 3,405 shares of the healthcare product maker’s stock worth $463,000 after purchasing an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New clinical evidence — The FreeDM2 randomized trial showed FreeStyle Libre continuous glucose monitoring produced meaningful improvements in HbA1c and more time-in-range for people with Type 2 diabetes on basal insulin, supporting adoption and longer-term revenue upside for Abbott’s diabetes business. Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
• Positive Sentiment: Brand/consumer engagement — Abbott relaunched its “Abbott Dream Team” program with Real Madrid, a marketing push that can boost awareness for consumer-facing segments (nutrition, diagnostics) and strengthen long-term end-market demand. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Positive Sentiment: Value narrative — Analyst commentary and stock-screen mentions (Zacks, dividend-aristocrat lists) emphasize ABT’s defensive characteristics, dividend safety and long-term value, which can support investor demand despite near-term noise. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Analyst views diverging — Coverage shows only small shifts in modeled fair value overall, but several analysts are revising targets and re-weighting execution risk vs. long-run growth; this creates mixed signals and short-term volatility. How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks
• Negative Sentiment: Near-term earnings reception — Q4 revenue came in below consensus while EPS roughly met estimates, and sector Q4 comparisons flagged pockets of weakness; that revenue miss likely pressured the stock. Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies – Diversified Stocks
• Negative Sentiment: Price-target actions — Citigroup trimmed its price target slightly (from $140 to $136) while keeping a buy rating; small cuts across some desks add downward pressure even if sentiment remains constructive. Benzinga: Citigroup price target cut

Insider Buying and Selling at Abbott Laboratories

In other news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 1.9%

NYSE:ABT opened at $108.18 on Friday. The firm has a market capitalization of $187.98 billion, a P/E ratio of 29.08, a PEG ratio of 1.75 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The company’s 50-day simple moving average is $114.91 and its 200 day simple moving average is $124.08.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ABT shares. Barclays cut their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Piper Sandler cut their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.